Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA METHOTREXATE INJECTION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION OVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
4.3 PRICING DYNAMICS
4.4 INDUSTRIAL INSIGHTS:
4.5 CONCLUSION:
5 NORTH AMERICA METHOTREXATE INJECTION MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED PREVALENCE OF CANCER
6.1.2 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT LUNG AND BREAST CANCER
6.1.3 RISE IN NUMBER OF PATIENTS WITH INFLAMMATORY DISEASES
6.2 RESTRAINTS
6.2.1 RISE IN COST OF METHOTREXATE
6.2.2 SIDE EFFECTS AND COMPLICATIONS WITH USE OF METHOTREXATE
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
6.4 CHALLENGES
6.4.1 STRINGENT RULES AND REGULATIONS
6.4.2 PRODUCT RECALLS
6.4.3 RISE IN COMPETITION BETWEEN MARKET PLAYERS
7 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 WITHOUT PRESERVATIVES
7.3 WITH PRESERVATIVES
8 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY TYPE
8.1 OVERVIEW
8.2 INJECTABLE SOLUTION
8.3 SELF-INJECTABLE SOLUTION
9 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY AVAILABILITY
9.1 OVERVIEW
9.2 25MG/ML
9.3 50MG/2ML
10 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 SOLUTION
10.3 POWDER
11 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 CANCER
11.2.1 BREAST CANCER
11.2.2 LUNG CANCER
11.2.3 HEAD AND NECK CANCER
11.2.4 BLOOD CANCER
11.2.5 GESTATIONAL TROPHOBLASTIC TUMORS
11.2.6 OSTEOSARCOMA
11.2.7 OTHERS
11.3 AUTOIMMUNE DISEASES
11.3.1 RHEUMATOID ARTHRITIS
11.3.2 PSORIASIS
11.3.3 LUPUS
11.3.4 LOCALIZED SCLERODERMA
11.3.5 SARCOIDOSIS
11.3.6 VASCULITIS
11.3.7 JUVENILE DERMATOMYOSITIS
11.3.8 OTHERS
11.4 PREGNANCY
12 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 ADULTS
12.3 GERIATRIC
12.4 PEDIATRICS
13 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INTRAMUSCULAR
13.3 INTRAVENOUS
13.4 INTRA-ARTERIAL
13.5 INTRATHECAL
14 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY COUNTRY
16.1 U.S.
16.2 CANADA
16.3 MEXICO
17 NORTH AMERICA METHOTREXATE INJECTION MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 PFIZER INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENT
19.2 ANTARES PHARMA
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 MEDEXUS PHARMACEUTICALS, INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENT
19.5 VIATRIS INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 ACCORD HEALTHCARE
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 CUMBERLAND PHARMACEUTICALS INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 HIKMA PHARMACEUTICALS PLC
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 PV PHARMA
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY AVAILABILITY, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA CANCER IN METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA AUTOIMMUNE DISEASES IN METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 13 U.S. METHOTREXATE INJECTION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 14 U.S. METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 U.S. METHOTREXATE INJECTION MARKET, BY AVAILABILITY, 2020-2029 (USD MILLION)
TABLE 16 U.S. METHOTREXATE INJECTION MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 17 U.S. METHOTREXATE INJECTION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 18 U.S. CANCER IN METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 U.S. AUTOIMMUNE DISEASES IN METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 U.S. METHOTREXATE INJECTION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 21 U.S. METHOTREXATE INJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 22 U.S. METHOTREXATE INJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 U.S. METHOTREXATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 CANADA METHOTREXATE INJECTION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 25 CANADA METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 26 CANADA METHOTREXATE INJECTION MARKET, BY AVAILABILITY, 2020-2029 (USD MILLION)
TABLE 27 CANADA METHOTREXATE INJECTION MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 28 CANADA METHOTREXATE INJECTION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 29 CANADA CANCER IN METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 CANADA AUTOIMMUNE DISEASES IN METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 CANADA METHOTREXATE INJECTION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 32 CANADA METHOTREXATE INJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 33 CANADA METHOTREXATE INJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 CANADA METHOTREXATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 MEXICO METHOTREXATE INJECTION MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 36 MEXICO METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 MEXICO METHOTREXATE INJECTION MARKET, BY AVAILABILITY, 2020-2029 (USD MILLION)
TABLE 38 MEXICO METHOTREXATE INJECTION MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 39 MEXICO METHOTREXATE INJECTION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 40 MEXICO CANCER IN METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 MEXICO AUTOIMMUNE DISEASES IN METHOTREXATE INJECTION MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 MEXICO METHOTREXATE INJECTION MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 43 MEXICO METHOTREXATE INJECTION MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 44 MEXICO METHOTREXATE INJECTION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 45 MEXICO METHOTREXATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA METHOTREXATE INJECTION MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA METHOTREXATE INJECTION MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA METHOTREXATE INJECTION MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA METHOTREXATE INJECTION MARKET: REGIONAL VS COUNTRY ANALYSIS
FIGURE 5 NORTH AMERICA METHOTREXATE INJECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA METHOTREXATE INJECTION MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA METHOTREXATE INJECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA METHOTREXATE INJECTION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA METHOTREXATE INJECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA METHOTREXATE INJECTION MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CANCERS AUTOIMMUNE DISEASES IS EXPECTED TO DRIVE THE NORTH AMERICA METHOTREXATE INJECTION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 WITHOUT PRESERVATIVES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA METHOTREXATE INJECTION MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA METHOTREXATE INJECTION MARKET
FIGURE 14 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY PRODUCT, 2021
FIGURE 15 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY PRODUCT, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY TYPE, 2021
FIGURE 19 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY AVAILABILITY, 2021
FIGURE 23 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY AVAILABILITY, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY AVAILABILITY, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY AVAILABILITY, LIFELINE CURVE
FIGURE 26 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY DOSAGE FORM, 2021
FIGURE 27 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 30 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY APPLICATION, 2021
FIGURE 31 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 34 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY AGE GROUP, 2021
FIGURE 35 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 38 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 39 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 40 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 41 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 42 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY END USER, 2021
FIGURE 43 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 44 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 45 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 47 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 48 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 49 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 NORTH AMERICA METHOTREXATE INJECTION MARKET: SNAPSHOT (2021)
FIGURE 51 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY COUNTRY (2021)
FIGURE 52 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 53 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 54 NORTH AMERICA METHOTREXATE INJECTION MARKET: BY PRODUCT (2022-2029)
FIGURE 55 NORTH AMERICA METHOTREXATE INJECTION MARKET: COMPANY SHARE 2021 (%)
